CA2850627C - Affenadenovirus (gorilla) or adenoviral vectors and methods of use - Google Patents
Affenadenovirus (gorilla) or adenoviral vectors and methods of use Download PDFInfo
- Publication number
- CA2850627C CA2850627C CA2850627A CA2850627A CA2850627C CA 2850627 C CA2850627 C CA 2850627C CA 2850627 A CA2850627 A CA 2850627A CA 2850627 A CA2850627 A CA 2850627A CA 2850627 C CA2850627 C CA 2850627C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- adenovirus
- acid sequence
- adenoviral vector
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title claims abstract description 230
- 241000282575 Gorilla Species 0.000 title description 8
- 238000000034 method Methods 0.000 title description 6
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 241
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 190
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 160
- 230000007812 deficiency Effects 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 18
- 108700019146 Transgenes Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 abstract description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 abstract description 6
- 101710145505 Fiber protein Proteins 0.000 abstract description 6
- 101710094396 Hexon protein Proteins 0.000 abstract description 6
- 101710173835 Penton protein Proteins 0.000 abstract description 5
- 150000001413 amino acids Chemical group 0.000 description 131
- 108090000623 proteins and genes Proteins 0.000 description 109
- 239000002773 nucleotide Substances 0.000 description 106
- 125000003729 nucleotide group Chemical group 0.000 description 106
- 125000000539 amino acid group Chemical group 0.000 description 59
- 230000006870 function Effects 0.000 description 51
- 230000002950 deficient Effects 0.000 description 46
- 102000004169 proteins and genes Human genes 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 32
- 230000010076 replication Effects 0.000 description 31
- 239000002245 particle Substances 0.000 description 18
- 230000037430 deletion Effects 0.000 description 17
- 238000012217 deletion Methods 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 15
- 210000000234 capsid Anatomy 0.000 description 15
- 239000013603 viral vector Substances 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 9
- 241000725643 Respiratory syncytial virus Species 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 4
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 4
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 4
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 4
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 4
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 4
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 4
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 4
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 4
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 4
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 4
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 4
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 4
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 4
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 4
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 4
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 4
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 4
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 4
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 4
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 4
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 4
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 4
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 4
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 4
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 4
- 241000658592 Gorilla beringei Species 0.000 description 4
- 241000202709 Gorilla beringei graueri Species 0.000 description 4
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 4
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 4
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 4
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 4
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 4
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 4
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 4
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 4
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 4
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 4
- 101710087110 ORF6 protein Proteins 0.000 description 4
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 4
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 4
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 4
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 4
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 4
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 4
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 4
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 4
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 4
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 4
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 4
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 4
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 4
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 4
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 4
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 4
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- 241000144282 Sigmodon Species 0.000 description 3
- -1 about 3 to about 1 Chemical class 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 108700025771 adenovirus penton Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000650678 Gorilla gorilla diehli Species 0.000 description 2
- 241000282578 Gorilla gorilla gorilla Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 241000711920 Human orthopneumovirus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 101710109576 Terminal protein Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000003682 DNA packaging effect Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001472503 Gorilla beringei beringei Species 0.000 description 1
- 101150032643 IVa2 gene Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 241001088892 Virus-associated RNAs Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161543652P | 2011-10-05 | 2011-10-05 | |
| US61/543,652 | 2011-10-05 | ||
| PCT/US2012/058978 WO2013052811A2 (en) | 2011-10-05 | 2012-10-05 | Adenoviral vectors and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2850627A1 CA2850627A1 (en) | 2013-04-11 |
| CA2850627C true CA2850627C (en) | 2024-05-21 |
Family
ID=47045180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2850627A Active CA2850627C (en) | 2011-10-05 | 2012-10-05 | Affenadenovirus (gorilla) or adenoviral vectors and methods of use |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9629906B2 (enExample) |
| EP (1) | EP2764013B1 (enExample) |
| JP (2) | JP6757120B2 (enExample) |
| CN (2) | CN107937440A (enExample) |
| BR (1) | BR112014008249B1 (enExample) |
| CA (1) | CA2850627C (enExample) |
| HK (1) | HK1252010A1 (enExample) |
| IN (1) | IN2014DN03061A (enExample) |
| WO (1) | WO2013052811A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013052859A2 (en) * | 2011-10-05 | 2013-04-11 | Genvec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
| CN103987726B (zh) | 2011-10-05 | 2017-10-03 | 金维克有限公司 | 猴(大猩猩)腺病毒或腺病毒载体及其使用方法 |
| JP6757120B2 (ja) | 2011-10-05 | 2020-09-16 | ジェンヴェック エルエルシー | アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法 |
| IN2014DN03005A (enExample) | 2011-10-05 | 2015-05-08 | Genvec Inc | |
| US9676824B2 (en) * | 2012-05-29 | 2017-06-13 | Genvec, Inc. | Herpes simplex virus vaccine |
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| CA3034124A1 (en) | 2016-08-23 | 2018-03-01 | Glaxosmithkline Biologicals Sa | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| US11155832B2 (en) | 2016-09-30 | 2021-10-26 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into T cells |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| ES2959811T3 (es) | 2016-12-09 | 2024-02-28 | Glaxosmithkline Biologicals Sa | Construcciones de adenovirus de chimpancé con antígenos de Lyssavirus |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| GB201701239D0 (en) | 2017-01-25 | 2017-03-08 | Glaxosmithkline Biologicals Sa | Novel formulation |
| WO2019016756A1 (en) | 2017-07-21 | 2019-01-24 | Glaxosmithkline Biologicals Sa | ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES |
| AU2019231652B2 (en) | 2018-03-06 | 2025-05-22 | Precigen, Inc. | Hepatitis B vaccines and uses of the same |
| AU2019231654B2 (en) | 2018-03-06 | 2025-12-11 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| EP3587581A1 (en) | 2018-06-26 | 2020-01-01 | GlaxoSmithKline Biologicals S.A. | Formulations for simian adenoviral vectors having enhanced storage stability |
| US20220403438A1 (en) | 2019-10-08 | 2022-12-22 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
| MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| ES2310924T3 (es) | 1993-07-13 | 2009-01-16 | Centelion | Vectores adenovirales defectivos y utilizacion en terapia genica. |
| WO1995016772A1 (en) | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| AU2249097A (en) | 1996-01-29 | 1997-08-20 | Georgetown University | Malaria vaccine based upon the addition of a msa1 peptide |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| WO2001016344A1 (fr) * | 1999-08-27 | 2001-03-08 | Transgene S.A. | Fibre adenovirale modifiee et utilisations |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| US6821519B2 (en) | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| US20040136963A1 (en) | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| US6677156B2 (en) | 2001-07-23 | 2004-01-13 | Genvec, Inc. | Non-adenoviral gene product-based complementing cells for adenoviral vectors |
| AU2002327380A1 (en) | 2001-07-23 | 2003-03-18 | Genvec, Inc. | Cells and methods for propagating adenoviral vectors |
| US6682929B2 (en) | 2001-07-23 | 2004-01-27 | Genvec, Inc. | Adenovector complementing cells |
| EP1425045A4 (en) | 2001-09-13 | 2004-11-10 | Genvec Inc | ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| KR100987360B1 (ko) * | 2001-11-21 | 2010-10-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법 |
| WO2005075506A1 (en) | 2004-01-09 | 2005-08-18 | The Scripps Research Institute | Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors |
| ES2871907T3 (es) * | 2004-01-23 | 2021-11-02 | Msd Italia Srl | Portadores de vacuna de adenovirus de chimpancé |
| CN101072879B (zh) * | 2004-10-13 | 2011-05-11 | 克鲁塞尔荷兰公司 | 改良的腺病毒载体及其应用 |
| JP4621743B2 (ja) | 2004-12-13 | 2011-01-26 | カンジ，インコーポレイテッド | 複製欠損アデノウイルスの産生のための細胞株 |
| WO2007027860A2 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2007073513A2 (en) | 2005-11-10 | 2007-06-28 | Genvec, Inc. | Method for propagating adenoviral vectors encoding inhibitory gene products |
| CA2658484A1 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
| DK2350269T3 (en) | 2008-10-31 | 2015-12-07 | Univ Pennsylvania | ABE ADENOVIRUS WITH SADV-46 HEXONCAPSIDE PROTEINS AND APPLICATIONS THEREOF |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| US8865182B2 (en) | 2009-07-31 | 2014-10-21 | Paxvax, Inc. | Adenoviral-based vectors |
| JP5980117B2 (ja) | 2009-11-09 | 2016-08-31 | ジェンヴェック，インコーポレーテッド | サルアデノウイルスベクターの増殖方法 |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| WO2013052859A2 (en) * | 2011-10-05 | 2013-04-11 | Genvec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
| JP6757120B2 (ja) * | 2011-10-05 | 2020-09-16 | ジェンヴェック エルエルシー | アーフェンアデノウイルス（ゴリラ）又はアデノウイルスベクター、及び使用方法 |
| IN2014DN03005A (enExample) * | 2011-10-05 | 2015-05-08 | Genvec Inc | |
| CN103987726B (zh) * | 2011-10-05 | 2017-10-03 | 金维克有限公司 | 猴(大猩猩)腺病毒或腺病毒载体及其使用方法 |
| EP2809346A1 (en) * | 2012-02-02 | 2014-12-10 | GenVec, Inc. | Adenoviral vector-based malaria vaccine |
| US9676824B2 (en) | 2012-05-29 | 2017-06-13 | Genvec, Inc. | Herpes simplex virus vaccine |
-
2012
- 2012-10-05 JP JP2014534773A patent/JP6757120B2/ja active Active
- 2012-10-05 CA CA2850627A patent/CA2850627C/en active Active
- 2012-10-05 WO PCT/US2012/058978 patent/WO2013052811A2/en not_active Ceased
- 2012-10-05 CN CN201711203173.3A patent/CN107937440A/zh active Pending
- 2012-10-05 EP EP12775112.1A patent/EP2764013B1/en active Active
- 2012-10-05 CN CN201280059668.2A patent/CN103974970B/zh active Active
- 2012-10-05 IN IN3061DEN2014 patent/IN2014DN03061A/en unknown
- 2012-10-05 BR BR112014008249-9A patent/BR112014008249B1/pt active IP Right Grant
- 2012-10-05 US US14/349,426 patent/US9629906B2/en active Active
-
2017
- 2017-04-20 US US15/492,016 patent/US10272162B2/en active Active
-
2018
- 2018-07-20 JP JP2018137238A patent/JP6970060B2/ja active Active
- 2018-09-04 HK HK18111339.7A patent/HK1252010A1/zh unknown
-
2019
- 2019-03-13 US US16/352,459 patent/US10792376B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014DN03061A (enExample) | 2015-05-15 |
| WO2013052811A3 (en) | 2013-06-20 |
| HK1252010A1 (zh) | 2019-05-10 |
| WO2013052811A2 (en) | 2013-04-11 |
| US10272162B2 (en) | 2019-04-30 |
| EP2764013B1 (en) | 2022-01-26 |
| JP6757120B2 (ja) | 2020-09-16 |
| BR112014008249B1 (pt) | 2022-03-15 |
| EP2764013A2 (en) | 2014-08-13 |
| US20190269794A1 (en) | 2019-09-05 |
| US9629906B2 (en) | 2017-04-25 |
| CN103974970B (zh) | 2018-01-02 |
| US20140248308A1 (en) | 2014-09-04 |
| US20170246318A1 (en) | 2017-08-31 |
| CN103974970A (zh) | 2014-08-06 |
| US10792376B2 (en) | 2020-10-06 |
| JP6970060B2 (ja) | 2021-11-24 |
| JP2018198603A (ja) | 2018-12-20 |
| JP2014530605A (ja) | 2014-11-20 |
| BR112014008249A2 (pt) | 2017-04-18 |
| CA2850627A1 (en) | 2013-04-11 |
| CN107937440A (zh) | 2018-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11359214B2 (en) | Simian (gorilla) adenovirus or adenoviral vectors and methods of use | |
| US10792376B2 (en) | Affenadenovirus (gorilla) or adenoviral vectors and methods of use | |
| US11034975B2 (en) | Affenadenovirus (gorilla) or adenoviral vectors and methods of use | |
| WO2013181128A1 (en) | Modified serotype 28 adenoviral vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171005 |
|
| EEER | Examination request |
Effective date: 20171004 |
|
| EEER | Examination request |
Effective date: 20171004 |
|
| EEER | Examination request |
Effective date: 20171004 |
|
| EEER | Examination request |
Effective date: 20171004 |
|
| EEER | Examination request |
Effective date: 20171004 |
|
| EEER | Examination request |
Effective date: 20171004 |